Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

NCT02853604 is registered in ClinicalTrials.gov with Advaxis, Inc. as lead sponsor.

NCT NCT02853604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02853604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Lead sponsor
Advaxis, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 15, 2015
Completion date
July 31, 2019
Enrollment
110 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cervical cancer, high risk cervical cancer